Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
A. Bazinet, F. Darbaniyan, E. Jabbour, G. Montalban-Bravo +19 more

